220 related articles for article (PubMed ID: 26873790)
1. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a dose-response relationship.
Siva S; Jackson P; Kron T; Bressel M; Lau E; Hofman M; Shaw M; Chander S; Pham D; Lawrentschuk N; Wong LM; Goad J; Foroudi F
Radiother Oncol; 2016 Mar; 118(3):540-6. PubMed ID: 26873790
[TBL] [Abstract][Full Text] [Related]
2. Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial (99m)Tc-DMSA SPECT/CT.
Jackson P; Foroudi F; Pham D; Hofman MS; Hardcastle N; Callahan J; Kron T; Siva S
Radiat Oncol; 2014 Nov; 9():253. PubMed ID: 25424613
[TBL] [Abstract][Full Text] [Related]
3. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
[TBL] [Abstract][Full Text] [Related]
4. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
[TBL] [Abstract][Full Text] [Related]
5. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
[TBL] [Abstract][Full Text] [Related]
7. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
[TBL] [Abstract][Full Text] [Related]
8. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
[TBL] [Abstract][Full Text] [Related]
9. Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma.
Reynolds HM; Parameswaran BK; Finnegan ME; Roettger D; Lau E; Kron T; Shaw M; Chander S; Siva S
PLoS One; 2018; 13(8):e0202387. PubMed ID: 30114235
[TBL] [Abstract][Full Text] [Related]
10. Low rate of severe-end-stage kidney disease after SABR for localised primary kidney cancer.
Ali M; Koo K; Chang D; Chan P; Oon SF; Moon D; Murphy DG; Eapen R; Goad J; Lawrentschuk N; Azad AA; Chander S; Shaw M; Hardcastle N; Siva S
Radiat Oncol; 2024 Feb; 19(1):23. PubMed ID: 38355495
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial.
Siva S; Pham D; Kron T; Bressel M; Lam J; Tan TH; Chesson B; Shaw M; Chander S; Gill S; Brook NR; Lawrentschuk N; Murphy DG; Foroudi F
BJU Int; 2017 Nov; 120(5):623-630. PubMed ID: 28188682
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Siva S; Correa RJM; Warner A; Staehler M; Ellis RJ; Ponsky L; Kaplan ID; Mahadevan A; Chu W; Gandhidasan S; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Louie AV
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):941-949. PubMed ID: 32562838
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity.
Pham D; Thompson A; Kron T; Foroudi F; Kolsky MS; Devereux T; Lim A; Siva S
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1061-8. PubMed ID: 25442039
[TBL] [Abstract][Full Text] [Related]
15. Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma.
Yamamoto T; Kadoya N; Takeda K; Matsushita H; Umezawa R; Sato K; Kubozono M; Ito K; Ishikawa Y; Kozumi M; Takahashi N; Katagiri Y; Onishi H; Jingu K
Radiat Oncol; 2016 May; 11():72. PubMed ID: 27229710
[TBL] [Abstract][Full Text] [Related]
16. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.
Correa RJM; Ahmad B; Warner A; Johnson C; MacKenzie MJ; Pautler SE; Bauman GS; Rodrigues GB; Louie AV
Radiat Oncol; 2018 Mar; 13(1):47. PubMed ID: 29558966
[TBL] [Abstract][Full Text] [Related]
17. CyberKnife for inoperable renal tumors: Canadian pioneering experience.
Nair VJ; Szanto J; Vandervoort E; Cagiannos I; Breau R; Malone C; Avruch L; Pantarotto J; Malone S
Can J Urol; 2013 Oct; 20(5):6944-9. PubMed ID: 24128835
[TBL] [Abstract][Full Text] [Related]
18. Dose-effect Relationship of Kidney Function After Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma: Trog 15.03 Fastrack Ii.
Gaudreault M; Hardcastle N; Jackson P; McIntosh L; Higgs B; Pryor D; Sidhom M; Dykyj R; Moore A; Kron T; Siva S
Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38679212
[TBL] [Abstract][Full Text] [Related]
19. Quantification of renal function following stereotactic body radiotherapy for pancreatic cancer: secondary dosimetric analysis of a prospective clinical trial.
Verma V; Bhirud AR; Denniston KA; Bennion NR; Lin C
Radiat Oncol; 2017 Apr; 12(1):71. PubMed ID: 28449702
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]